Salud financiera de hoja de balance de IGM Biosciences
Salud financiera controles de criterios 6/6
IGM Biosciences tiene un patrimonio de los accionistas total de $203.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $423.4M y $220.2M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$337.68m |
| Patrimonio | US$203.23m |
| Total pasivo | US$220.18m |
| Activos totales | US$423.41m |
Actualizaciones recientes sobre salud financiera
Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28
We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09Recent updates
Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($347.6M) de IGMS superan a sus pasivos a corto plazo ($42.5M).
Pasivo a largo plazo: Los activos a corto plazo de IGMS ($347.6M) superan a sus pasivos a largo plazo ($177.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: IGMS está libre de deudas.
Reducción de la deuda: IGMS actualmente no tiene deuda, sin embargo, no podemos comparar con hace 5 años ya que no disponemos de datos de ese periodo.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: IGMS has sufficient cash runway for more than a year based on its current free cash flow.
Pronóstico de cash runway: IGMS dispone de suficiente cash runway para 1.8 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 27.9% cada año.